Phorbol ester phorbol-12-myristate-13-acetate induces epithelial to mesenchymal transition in human prostate cancer ARCaPE cells

Prostate

Volumn 70, Issue 10, 2010, Pages 1119-1126

  He, Hui ^a   Davidson, Alec J ^b   Wu, Daqing ^c   Marshall, Fray F ^c   Chung, Leland W K ^c   Zhau, Haiyen E ^c   He, Dalin ^a   Wang, Ruoxiang ^c  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b MOREHOUSE SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epithelial to mesenchymal transition; Metastasis; Phorbol 12 myristate 13 acetate; Prostate cancer progression; Protein kinase C

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 5 METHOXY 1H INDOL 3 YL] 3 (1H INDOL 3 YL)MALEIMIDE; BETA ACTIN; CYTOKERATIN 18; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C; UVOMORULIN; VIMENTIN; 2 (1 (3 DIMETHYLAMINOPROPYL) 5 METHOXYINDOL 3 YL) 3 (1H INDOL 3 YL)MALEIMIDE; 2-(1-(3-DIMETHYLAMINOPROPYL)-5-METHOXYINDOL-3-YL)-3-(1H-INDOL-3-YL)MALEIMIDE; BISINDOLYLMALEIMIDE; CARCINOGEN; INDOLE DERIVATIVE; ISOENZYME; MALEIMIDE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; METASTASIS; MICROPHOTOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA TRANSLATION; WESTERN BLOTTING; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; EPITHELIUM CELL; MALE; MESODERM; METABOLISM; PATHOLOGY; PHASE CONTRAST MICROSCOPY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR CELL LINE; ULTRASTRUCTURE;

BLOTTING, WESTERN; CARCINOGENS; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL CELLS; HUMANS; INDOLES; ISOENZYMES; MALE; MALEIMIDES; MESODERM; MICROSCOPY, PHASE-CONTRAST; PROSTATIC NEOPLASMS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; STROMAL CELLS; TETRADECANOYLPHORBOL ACETATE;

EID: 77953422840     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21146     Document Type: Article

References (38)

1. Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel) 1995;154:8-20.
2. Hay ED, Zuk A. Transformations between epithelium and mesenchyme: Normal, pathological, and experimentally induced. Am J Kidney Dis 1995;26:678-690.
3. Shook D, Keller R. Mechanisms, mechanics and function of epithelial-mesenchymal transitions in early development. Mech Dev 2003;120:1351-1383. (Pubitemid 37421168)
4. Baum B, Settleman J, Quinlan MP.Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol 2008;19:294-308.
5. Perez-Pomares JM, Munoz-Chapuli R. Epithelial-mesenchymal transitions: A mesodermal cell strategy for evolutive innovation in Metazoans. Anat Rec 2002;268:343-351.
6. Zhau HE, Odero-Marah V, Lue HW, Nomura T, Wang R, Chu G, Liu ZR, Zhou BP, Huang WC, Chung LW. Epithelial to mesenchymal transition (EMT) in human prostate cancer: Lessons learned from ARCaP model. Clin Exp Metastasis 2008; 25:601-610.
7. Lawrence MG, Veveris-Lowe TL, Whitbread AK, Nicol DL, Clements JA. Epithelial-mesenchymal transition in prostate cancer and the potential role of kallikrein serine proteases. Cells Tissues Organs 2007;185:111-115.
8. Xu J, Wang R, Xie ZH, Odero-Marah V, Pathak S, Multani A, Chung LW, Zhau HE. Prostate cancer metastasis: Role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate 2006;66:1664-1673.
9. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 2007;213:374-383. (Pubitemid 47509716)
10. Cheng L, Nagabhushan M, Pretlow TP, Amini SB, Pretlow TG. Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol 1996;148:1375-1380. (Pubitemid 26135881)
11. Nagle RB. Intermediate filament expression in prostate cancer. Cancer Metastasis Rev 1996;15:473-482.
12. Odero-Marah VA, Wang R, Chu G, Zayzafoon M, Xu J, Shi C, Marshall FF, Zhau HE, Chung LW. Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res 2008;18:858-870.
13. Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, Tighiouart M, Liu T, Simons JW, O'Regan RM. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 2008;68:2479-2488.
14. He H, Yang X, Davidson AJ, Wu D, Marshall FF, Chung LW, Zhau HE, Wang R. Progressive epithelial to mesenchymal transitions in ARCaP(E) prostate cancer cells during xenograft tumor formation and metastasis. Prostate 2009. [Nov. 13, Epub ahead of print].
15. Zhau HY, Chang SM, Chen BQ, Wang Y, Zhang H, Kao C, Sang QA, Pathak SJ, Chung LW. Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci USA 1996;93:15152-15157. (Pubitemid 27009568)
16. Zhau HE, Li CL, Chung LW. Establishment of human prostate carcinoma skeletal metastasis models. Cancer 2000;88:2995-3001.
17. Ohno S, Akita Y, Hata A, Osada S, Kubo K, Konno Y, Akimoto K, Mizuno K, Saido T, Kuroki T, Suzuki K. Structural and functional diversities of a family of signal transducing protein kinases, protein kinase C family; two distinct classes of PKC, conventional cPKC and novel nPKC. Adv Enzyme Regul 1991; 31:287-303.
18. Baird WM, Boutwell RK. Tumor-promoting activity of phorbol and four diesters of phorbol in mouse skin. Cancer Res 1971;31: 1074-1079.
19. Furstenberger G, Berry DL, Sorg B, Marks F. Skin tumor promotion by phorbol esters is a two-stage process. Proc Natl Acad Sci USA 1981;78:7722-7726.
20. Scribner JD, Boutwell RK. Inflammation and tumor promotion: Selective protein induction in mouse skin by tumor promoters. Eur J Cancer 1972;8:617-621.
21. Feuerstein N, Cooper HL. Studies of the differentiation of promyelocytic cells by phorbol ester. I. Induction of discrete membrane proteins characteristic of monocytes and expression of motility functions in HL-60 cells following differentiation by phorbol ester. Biochim Biophys Acta 1984;781:239-246.
22. Lee EC, Tu RS, Fantone JC, Varani J. Functional responses of tumor cells to phorbol esters: Role for prostaglandins. Oncology 1984;41:210-216. (Pubitemid 14101535)
23. Basu A. The potential of protein kinase C as a target for anticancer treatment. Pharmacol Ther 1993;59:257-280.
24. Liu WS, Heckman CA. The sevenfold way of PKC regulation. Cell Signal 1998;10:529-542.
25. Heikkila J, Jalava A, Eriksson K. The selective protein kinase C inhibitor GF 109203X inhibits phorbol ester-induced morphological and functional differentiation of SH-SY5Y human neuroblastoma cells. Biochem Biophys Res Commun 1993;197:1185-1193.
26. Toullec D, Pianetti P, Coste H, Bellevergue P, Grand-Perret T, Ajakane M, Baudet V, Boissin P, Boursier E, Loriolle F, Duhamel L, Charon D, Kirilovski J. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem 1991;266:15771-15781. (Pubitemid 21907725)
27. Joyce T, Cantarella D, Isella C, Medico E, Pintzas A. A molecular signature for Epithelial to Mesenchymal transition in a human colon cancer cell system is revealed by large-scale microarray analysis. Clin Exp Metastasis 2009;26:569-587.
28. Hofmann J. Modulation of protein kinase C in antitumor treatment. Rev Physiol Biochem Pharmacol 2001;142:1-96.
29. Dong Z, Huang C, Ma WY. PI-3 kinase in signal transduction, cell transformation, and as a target for chemoprevention of cancer. Anticancer Res 1999;19:3743-3747.
30. Martin PM, Hussaini IM. PKC eta as a therapeutic target in glioblastoma multiforme. Expert Opin Ther Targets 2005;9:299-313.
31. Ali AS, Ali S, El-Rayes BF, Philip PA, Sarkar FH. Exploitation of protein kinase C: A useful target for cancer therapy. Cancer Treat Rev 2009;35:1-8.
32. Mischiati C, Melloni E, Corallini F, Milani D, Bergamini C, Vaccarezza M. Potential role of PKC inhibitors in the treatment of hematological malignancies. Curr Pharm Des 2008;14:2075-2084.
33. Fields AP, Frederick LA, Regala RP. Targeting the oncogenic protein kinase Ciota signalling pathway for the treatment of cancer. Biochem Soc Trans 2007;35:996-1000.
34. Podar K, Raab MS, Chauhan D, Anderson KC. The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. Expert Opin Investig Drugs 2007;16:1693-1707.
35. Fields AP, Regala RP. Protein kinase C iota: Human oncogene, prognostic marker and therapeutic target. Pharmacol Res 2007; 55:487-497.
36. Brembeck FH, Rosario M, Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev 2006;16:51-59.
37. Cowin P, Rowlands TM, Hatsell SJ. Cadherins and catenins in breast cancer. Curr Opin Cell Biol 2005;17:499-508.
38. Salon C, Lantuejoul S, Eymin B, Gazzeri S, Brambilla C, Brambilla E. The E-cadherin-beta-catenin complex and its implication in lung cancer progression and prognosis. Future Oncol 2005;1:649-660.